Preclinical safety testing of biotechnology-derived pharmaceuticals

The unique and complex nature of biotechnology-derived pharmaceuticals has meant that it is often not possible to follow the conventional safety testing programs used for chemicals, and hence they are evaluated on a case-by-case basis. Nonclinical safety testing programs must be rationally designed with a strong scientific understanding of the product, including its method of manufacture, purity, sequence, structure, species specificity, pharmacological and immunological effects, and intended clinical use. This knowledge, coupled with a firm understanding of the regulatory requirements for particular product types, will ensure that the most sensitive and regulatory-compliant test systems are used to optimize the chances of gaining regulatory approval for clinical testing or marketing authorization in the shortest possible time frame.

[1]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Ronald G. Crystal,et al.  The gene as the drug , 1995, Nature Medicine.

[3]  W. Bornmann,et al.  Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. , 2002, Vaccine.

[4]  C. Macken,et al.  A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  W Suter,et al.  Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung. , 1999, Mutation research.

[6]  S. Vadhan-Raj.  Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. , 2000, Seminars in hematology.

[7]  A. Piersma,et al.  Developmental toxicity but no immunotoxicity in the rat after prenatal exposure to diethylstilbestrol. , 2002, Toxicology.

[8]  M. Estes,et al.  Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge , 1998, Journal of Virology.

[9]  E. Kontseková,et al.  Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects. , 1999, Acta virologica.

[10]  R. Rappuoli,et al.  The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens To Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin , 2002, Infection and Immunity.

[11]  K. Timmis,et al.  Oral Somatic Transgene Vaccination Using Attenuated S. typhimurium , 1997, Cell.

[12]  R. Gupta,et al.  Adjuvants for human vaccines--current status, problems and future prospects. , 1995, Vaccine.

[13]  J. Exon,et al.  Immunotoxicity testing in the rat: an improved multiple assay model. , 1990, International journal of immunopharmacology.

[14]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[15]  S. Stevanović,et al.  Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. , 2001, Journal of immunological methods.

[16]  H. Chiou,et al.  Gene therapy strategies for the treatment of chronic viral hepatitis , 2001, Expert opinion on biological therapy.

[17]  A. Purcell,et al.  The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. , 2002, Current drug targets.

[18]  H. Inagaki,et al.  Acute and subchronic immunotoxicity of p-chloronitrobenzene in mice. I. Effect on natural killer, cytotoxic T-lymphocyte activities and mitogen-stimulated lymphocyte proliferation. , 1998, Toxicology.

[19]  D. Gill,et al.  A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis , 1997, Gene Therapy.

[20]  J. Glorioso,et al.  Gene delivery using herpes simplex virus vectors. , 2002, DNA and cell biology.

[21]  R. Mulligan,et al.  The basic science of gene therapy. , 1993, Science.

[22]  M. Bleavins,et al.  Cynomolgus monkeys (Macaca fascicularis) in preclinical immune function safety testing: development of a delayed-type hypersensitivity procedure. , 1995, Toxicology.

[23]  Mary S. Wu,et al.  Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. , 2000, Vaccine.

[24]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[25]  S. Irwin,et al.  Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse , 1968, Psychopharmacologia.

[26]  W. Hamilton,et al.  Chimeric Plant Virus Particles Administered Nasally or Orally Induce Systemic and Mucosal Immune Responses in Mice , 1999, Journal of Virology.

[27]  W. W. Nichols,et al.  Potential DNA Vaccine Integration into Host Cell Genome , 1995, Annals of the New York Academy of Sciences.

[28]  P. Robbins,et al.  Gene therapy strategies to prevent autoimmune disorders. , 2002, Current gene therapy.

[29]  Alan E. Smith,et al.  Viral vectors in gene therapy. , 1995, Annual review of microbiology.

[30]  A. Hemminki,et al.  Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). , 2002, International journal of oncology.

[31]  W. Anderson,et al.  Lymphocyte gene therapy. , 1991, Human gene therapy.

[32]  J. Kline.  DNA therapy for asthma , 2002, Current opinion in allergy and clinical immunology.

[33]  E. Borden,et al.  New and modified interferon alfas: Preclinical and clinical data , 2003, Current oncology reports.

[34]  Antibody Engineering and Expression , 2001 .

[35]  A. Barbero,et al.  Growth factor supplemented matrigel improves ectopic skeletal muscle formation—a cell therapy approach , 2001, Journal of cellular physiology.

[36]  A. Chang,et al.  Applications of gene transfer to cellular immunotherapy. , 2002, Surgical oncology clinics of North America.

[37]  P. Carter,et al.  Engineering antibodies for imaging and therapy. , 1997, Current opinion in biotechnology.

[38]  J. Egrie,et al.  Development and characterization of novel erythropoiesis stimulating protein (NESP) , 2001, British Journal of Cancer.

[39]  G. Treacy.  Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFa monoclonal antibody , 2000, Human & experimental toxicology.

[40]  R. Jordan,et al.  Abciximab Readministration: Results of the ReoPro Readministration Registry , 2001, Circulation.

[41]  K. Ekdahl,et al.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation , 2002, The Lancet.

[42]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[43]  B. Sangro,et al.  Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. , 2003, Current gene therapy.

[44]  C. Yang,et al.  Thrombocytopenia caused by the development of antibodies to thrombopoietin. , 2001, Blood.

[45]  G. Dougan,et al.  Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. , 2003, Vaccine.

[46]  L. Turin,et al.  What's going on in vaccine technology? , 1997, Medicinal research reviews.

[47]  L. Bonetta.  Leukemia case triggers tighter gene-therapy controls , 2002, Nature Medicine.

[48]  H Bönig,et al.  Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF) – results of a prospective randomised monocentre study , 2001, Bone Marrow Transplantation.

[49]  R. Weiss,et al.  Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. , 2002, Vaccine.

[50]  M. Otagiri,et al.  Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin , 2002, Pharmaceutical Research.

[51]  M. Sonnenblick,et al.  Cardiotoxicity of interferon. A review of 44 cases. , 1991, Chest.

[52]  R. Schaub,et al.  Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. , 2002, Seminars in thrombosis and hemostasis.

[53]  H. Schuppe,et al.  A local lymph node assay to analyse immunosuppressive effects of topically applied drugs. , 1997, European journal of pharmacology.

[54]  J. Sandhu.  Engineered human vaccines. , 1994, Critical reviews in biotechnology.

[55]  P. Hudson,et al.  Recombinant antibody fragments. , 1998, Current opinion in biotechnology.

[56]  D. Weilguny,et al.  The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model , 1994, Diabetologia.

[57]  I. S. Johnson.  Human insulin from recombinant DNA technology. , 1983, Science.

[58]  C. Fournier,et al.  Syngeneic fibroblasts transfected with a plasmid encoding interleukin‐4 as non‐viral vectors for anti‐inflammatory gene therapy in collagen‐induced arthritis , 2002, The journal of gene medicine.

[59]  A. Badger,et al.  Preclinical development of keliximab, a Primatized™ anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies , 2000, Human & experimental toxicology.

[60]  P. Barrow.  Reproductive toxicology studies and immunotherapeutics. , 2003, Toxicology.

[61]  T. Mor,et al.  Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. , 2002, Trends in molecular medicine.

[62]  P. Barrow,et al.  Reproductive toxicity testing of vaccines. , 2003, Toxicology.

[63]  A. McMichael,et al.  Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. , 2002, Vaccine.

[64]  Gary Walsh,et al.  Biopharmaceuticals: Biochemistry and Biotechnology , 1998 .

[65]  Michael A. Gonzalez,et al.  From genome to vaccine: in silico predictions, ex vivo verification. , 2001, Vaccine.

[66]  D. Zallen.  US gene therapy in crisis. , 2000 .

[67]  R. Weeratna,et al.  Novel adjuvant systems. , 2001, Current drug targets. Infectious disorders.

[68]  K A Chester,et al.  Clinical issues in antibody design. , 1995, Trends in biotechnology.

[69]  R. Compans,et al.  Enhancement of Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus , 2003, Journal of Virology.

[70]  J. Prieto,et al.  Cytokine gene transfer into dendritic cells for cancer treatment. , 2002, Current gene therapy.

[71]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[72]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[73]  W. Hamilton,et al.  Cowpea mosaic virus as a vaccine carrier of heterologous antigens , 2001, Molecular biotechnology.

[74]  P. Rakoczy,et al.  Adenovirus and adeno-associated virus vectors. , 2002, DNA and cell biology.

[75]  S. Hanauer.  Review article: safety of infliximab in clinical trials , 1999, Alimentary pharmacology & therapeutics.

[76]  T Friedmann,et al.  Overcoming the obstacles to gene therapy. , 1997, Scientific American.

[77]  Marjan,et al.  of Healthy Volunteers ) Mutations by ssaV Secretion System ( Pathogenicity Island 2 Type III Salmonella and aroC Derivatives Harboring Defined Salmonella enterica Characterization of , 2002 .

[78]  G. Weinbauer,et al.  Reproductive/developmental toxicity and immunotoxicity assessment in the nonhuman primate model. , 2003, Toxicology.

[79]  R. Herndon,et al.  Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.

[80]  D. Montgomery,et al.  Gene Therapy with Vascular Endothelial Growth Factor Reduces Angina , 2003, The Journal of cardiovascular nursing.